[
  {
    "ts": null,
    "headline": "Is Merck & Co., Inc. (MRK) the Best Consistent Dividend Stock to Buy?",
    "summary": "We recently published a list of 12 Best Consistent Dividend Stocks to Buy. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best consistent dividend stocks to buy. Over the past two years, persistently high inflation has led to increased borrowing costs, creating a […]",
    "url": "https://finnhub.io/api/news?id=525a360bdc738baf769aa28c33f55e38678e0354fc94de4ab1f7305eb5a4f799",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743026986,
      "headline": "Is Merck & Co., Inc. (MRK) the Best Consistent Dividend Stock to Buy?",
      "id": 133462082,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published a list of 12 Best Consistent Dividend Stocks to Buy. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best consistent dividend stocks to buy. Over the past two years, persistently high inflation has led to increased borrowing costs, creating a […]",
      "url": "https://finnhub.io/api/news?id=525a360bdc738baf769aa28c33f55e38678e0354fc94de4ab1f7305eb5a4f799"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Merck (MRK): “I Like It at This Level – But I Like Bristol-Myers Even More!”",
    "summary": "We recently published a list of Jim Cramer Recently Put These 10 Stocks Under Spotlight. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other stocks that Jim Cramer discussed recently. On Monday, Jim Cramer, host of Mad Money, shared his thoughts on how the […]",
    "url": "https://finnhub.io/api/news?id=88cdf4020654f947642c32f12b36a0002f2f93483992fc0c041dc81148e911fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743011113,
      "headline": "Jim Cramer on Merck (MRK): “I Like It at This Level – But I Like Bristol-Myers Even More!”",
      "id": 133462083,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published a list of Jim Cramer Recently Put These 10 Stocks Under Spotlight. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other stocks that Jim Cramer discussed recently. On Monday, Jim Cramer, host of Mad Money, shared his thoughts on how the […]",
      "url": "https://finnhub.io/api/news?id=88cdf4020654f947642c32f12b36a0002f2f93483992fc0c041dc81148e911fa"
    }
  },
  {
    "ts": null,
    "headline": "Merck (NYSE:MRK) Gains EC Approval For CAPVAXIVE® Amid Recent 7% Share Price Dip",
    "summary": "Merck (NYSE:MRK) has recently achieved a significant milestone with the European Commission's approval of its pneumococcal vaccine CAPVAXIVE®, boosting its portfolio in the vaccines market. Despite this positive development, the company's share price encountered a 1.82% decline over the last month, a period marked by substantial turmoil across global markets. Influenced by concerns related to potential U.S. tariffs and the broader selloff in the technology sector, many investors were...",
    "url": "https://finnhub.io/api/news?id=c891a3449cf3502f788d0a0f82d29be4fb75dbd18422f911220c34c4e3450a5b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743010330,
      "headline": "Merck (NYSE:MRK) Gains EC Approval For CAPVAXIVE® Amid Recent 7% Share Price Dip",
      "id": 133462084,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (NYSE:MRK) has recently achieved a significant milestone with the European Commission's approval of its pneumococcal vaccine CAPVAXIVE®, boosting its portfolio in the vaccines market. Despite this positive development, the company's share price encountered a 1.82% decline over the last month, a period marked by substantial turmoil across global markets. Influenced by concerns related to potential U.S. tariffs and the broader selloff in the technology sector, many investors were...",
      "url": "https://finnhub.io/api/news?id=c891a3449cf3502f788d0a0f82d29be4fb75dbd18422f911220c34c4e3450a5b"
    }
  },
  {
    "ts": null,
    "headline": "5 Reasons To Buy Regenxbio Right Now",
    "summary": "Regenxbio Inc. is ranked a Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and major buyout potential. Click for more on RGNX stock.",
    "url": "https://finnhub.io/api/news?id=8a40b480c8d306b7e091b768b67a23d4ebda58dfb202802efbf685da9ecf8ceb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742992278,
      "headline": "5 Reasons To Buy Regenxbio Right Now",
      "id": 133458187,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1452912285/image_1452912285.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Regenxbio Inc. is ranked a Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and major buyout potential. Click for more on RGNX stock.",
      "url": "https://finnhub.io/api/news?id=8a40b480c8d306b7e091b768b67a23d4ebda58dfb202802efbf685da9ecf8ceb"
    }
  },
  {
    "ts": null,
    "headline": "Chevron, McDonald's share gains contribute to Dow's 118-point jump",
    "summary": "Chevron, McDonald's share gains contribute to Dow's 118-point jump",
    "url": "https://finnhub.io/api/news?id=5dc775908e4183e81d2ef577dbfde84a64b6fce93c1704e497f60bc002ac4b94",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742987880,
      "headline": "Chevron, McDonald's share gains contribute to Dow's 118-point jump",
      "id": 133463167,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Chevron, McDonald's share gains contribute to Dow's 118-point jump",
      "url": "https://finnhub.io/api/news?id=5dc775908e4183e81d2ef577dbfde84a64b6fce93c1704e497f60bc002ac4b94"
    }
  },
  {
    "ts": null,
    "headline": "Forget S&P 500 And Buy These Dividend Icons Instead",
    "summary": "Forget S&P 500 And Buy These Dividend Icons Instead",
    "url": "https://finnhub.io/api/news?id=b21b4fa1102f750ba2be2c50300bffb1ab17c0c44eb5f9e97fd8194aad8c643d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742986800,
      "headline": "Forget S&P 500 And Buy These Dividend Icons Instead",
      "id": 133456965,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b21b4fa1102f750ba2be2c50300bffb1ab17c0c44eb5f9e97fd8194aad8c643d"
    }
  },
  {
    "ts": null,
    "headline": "European Commission (EC) Approves Merck’s CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults",
    "summary": "RAHWAY, N.J., March 26, 2025--European Commission (EC) Approves Merck’s CAPVAXIVE® for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults",
    "url": "https://finnhub.io/api/news?id=df902931efd098566316e387dfdb95be695e60a249e2369c94ae6cbcce2c9f64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742985900,
      "headline": "European Commission (EC) Approves Merck’s CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults",
      "id": 133448351,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., March 26, 2025--European Commission (EC) Approves Merck’s CAPVAXIVE® for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults",
      "url": "https://finnhub.io/api/news?id=df902931efd098566316e387dfdb95be695e60a249e2369c94ae6cbcce2c9f64"
    }
  },
  {
    "ts": null,
    "headline": "Merck: pneumococcal vaccine approved in EU",
    "summary": "On Wednesday Merck announced that the European Commission has approved its pneumococcal vaccine Capvaxive for the prevention of invasive pneumococcal disease in adults.The authorisation granted by...",
    "url": "https://finnhub.io/api/news?id=680e827af7929f546ec2898dd1cb154d59e0975baf588375b31d8652a4e624bf",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742982989,
      "headline": "Merck: pneumococcal vaccine approved in EU",
      "id": 133454779,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "On Wednesday Merck announced that the European Commission has approved its pneumococcal vaccine Capvaxive for the prevention of invasive pneumococcal disease in adults.The authorisation granted by...",
      "url": "https://finnhub.io/api/news?id=680e827af7929f546ec2898dd1cb154d59e0975baf588375b31d8652a4e624bf"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co.: Looming Patent Expiries For Key Drugs Weakens Longer-Term Outlook",
    "summary": ">40% of Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.",
    "url": "https://finnhub.io/api/news?id=9b4e78b04ae3afbd575bac37d78408711bc7628cc7a9328f60d9eaba4b50e894",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742981285,
      "headline": "Merck & Co.: Looming Patent Expiries For Key Drugs Weakens Longer-Term Outlook",
      "id": 133452861,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": ">40% of Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.",
      "url": "https://finnhub.io/api/news?id=9b4e78b04ae3afbd575bac37d78408711bc7628cc7a9328f60d9eaba4b50e894"
    }
  },
  {
    "ts": null,
    "headline": "Why Merck & Co. Inc. (MRK) Performed Worst On Tuesday?",
    "summary": "We recently published a list of Pulse of The Market: Tuesday’s 10 Worst Performers. In this article, we are going to take a look at where Merck & Co. Inc. (NYSE:MRK) stands against other Tuesday’s worst performers. Wall Street finished Tuesday’s trading in a lackluster fashion, with all major indices ending in the green territory, […]",
    "url": "https://finnhub.io/api/news?id=6cc650cc63e57b566a04b0a781da3f8572ddc8fae5c863e3e0ea20c6e128d3af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742980790,
      "headline": "Why Merck & Co. Inc. (MRK) Performed Worst On Tuesday?",
      "id": 133447202,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published a list of Pulse of The Market: Tuesday’s 10 Worst Performers. In this article, we are going to take a look at where Merck & Co. Inc. (NYSE:MRK) stands against other Tuesday’s worst performers. Wall Street finished Tuesday’s trading in a lackluster fashion, with all major indices ending in the green territory, […]",
      "url": "https://finnhub.io/api/news?id=6cc650cc63e57b566a04b0a781da3f8572ddc8fae5c863e3e0ea20c6e128d3af"
    }
  },
  {
    "ts": null,
    "headline": "European Commission (EC) Approves Merck's CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine)",
    "summary": "Merck & Co Inc: * EUROPEAN COMMISSION APPROVES MERCK’S CAPVAXIVE® FOR PREVENTION OFINVASIVE PNEUMOCOCCAL DISEASE AND PNEUMOCOCCAL PNEUMONIA INADULTSSource text:Further company...",
    "url": "https://finnhub.io/api/news?id=af5a600b84f8886fcda363802934b302973821177d861b62e2956c66a2e5e3a2",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742975482,
      "headline": "European Commission (EC) Approves Merck's CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine)",
      "id": 133447909,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck & Co Inc: * EUROPEAN COMMISSION APPROVES MERCK’S CAPVAXIVE® FOR PREVENTION OFINVASIVE PNEUMOCOCCAL DISEASE AND PNEUMOCOCCAL PNEUMONIA INADULTSSource text:Further company...",
      "url": "https://finnhub.io/api/news?id=af5a600b84f8886fcda363802934b302973821177d861b62e2956c66a2e5e3a2"
    }
  },
  {
    "ts": null,
    "headline": "Merck Gets European Commission Approval of Capvaxive Vaccine",
    "summary": "By Colin Kellaher Merck & Co. has won approval from the European Commission of its Capvaxive pneumococcal disease vaccine for adults. The Rahway, N.J., drugmaker on Wednesday said the...",
    "url": "https://finnhub.io/api/news?id=f3e44f3408bcbe0a34fb762a461bdd0d0f820857a4089ed4a9c87f46831beae7",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742973015,
      "headline": "Merck Gets European Commission Approval of Capvaxive Vaccine",
      "id": 133447624,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Merck & Co. has won approval from the European Commission of its Capvaxive pneumococcal disease vaccine for adults. The Rahway, N.J., drugmaker on Wednesday said the...",
      "url": "https://finnhub.io/api/news?id=f3e44f3408bcbe0a34fb762a461bdd0d0f820857a4089ed4a9c87f46831beae7"
    }
  }
]